[The functional morphology of the thymus in systemic lupus erythematosus and its characteristics during immunodepressive and immunostimulating therapies].
Functional morphology of thymus is studied in 10 autopsy cases of systemic lupus erythematosus (SLE) in patients of 8 to 30 years, treated with high doses of glucocorticosteroids (GCS) alone or in combination with tactivin or without immunomodulating therapy. Manifestations of SLE are interstitial thymitis and pronounced thymus parenchyma atrophy which is present regardless of therapy. In the absence of the therapy with high doses of GCS, increase of perivascular spaces of thymus lobules with the appearance in these spaces of lymphoid follicles results in the false increase of the thymus volume and weight simulating its hyperplasia. GCS therapy enhances parenchymal atrophy and decreases the size of perivascular spaces. The use of tactivin against this background results in some normalization of thymic structure enhancing the lymphocyte proliferative activity. Effect of tactivin is masked by a more powerful GCS therapy.
Zaĭrat'iants
O V
OV
Kartasheva
V I
VI
Tarasova
L R
LR
Trishkina
N V
NV
Khavinson
V Kh
VKh
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001327:Autoimmune Diseases / Q000503:physiopathology* / Q000628:therapy; D002648:Child; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007150:Immunohistochemistry; D007165:Immunosuppression Therapy; D008180:Lupus Erythematosus, Systemic / Q000503:physiopathology* / Q000628:therapy; D008199:Lymphadenitis / Q000503:physiopathology / Q000628:therapy; D010455:Peptides / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D013949:Thymus Extracts / Q000008:administration & dosage; D013950:Thymus Gland / Q000503:physiopathology*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin; D011239:Prednisolone
Funktsional'naia morfologiia timusa pri sistemnoĭ krasnoĭ volchanke, ee osobennosti pri immunodepressivnoĭ i immunostimuliruiushcheĭ terapii.